Armis Biopharma Announces Receipt of a $20.3 Million Contract with the Defense Threat Reduction Agency to Develop Veriox® DECON for Battlefield Wounds

FORT COLLINS, Colo., Sept. 28, 2023 /PRNewswire/ — Armis Biopharma, Inc. announced today that the company received a $20.3 million contract from the Defense Threat Reduction Agency (DTRA) to develop its proprietary Veriox® DECON chemical warfare agent (CWA) decontamination product for…

Click here to view original post